it is especially effective against species of pseudomonas it was patented in 1965 and approved for medical use in 1974 like all aminoglycosides tobramycin does not pass the gastro intestinal tract so for systemic use it can only be given intravenously or by injection into a muscle ophthalmic tobramycin only tobrex or combined with dexamethasone sold as tobradex and nebulised formulations both have low systemic absorption the formulation for injection is branded nebcin the nebulised formulation brand name tobi is indicated in the treatment of exacerbations of chronic infection with pseudomonas aeruginosa in patients diagnosed with cystic fibrosis a proprietary formulation of micronized nebulized tobramycin has been tested as a treatment for bacterial sinusitis tobrex is a 0 3 tobramycin sterile ophthalmic solution is produced by bausch lomb pharmaceuticals benzalkonium chloride 0 01 is added as a preservative it is available by prescription only in the united states and canada in certain countries it is available over the counter tobrex and tobradex are indicated in the treatment of superficial infections of the eye such as bacterial conjunctivitis tobramycin injection is also indicated for various severe or life threatening gram negative infections meningitis in neonates brucellosis pelvic inflammatory disease yersinia pestis